Q2 EPS Forecast for CRISPR Therapeutics Decreased by Analyst

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.78) per share for the quarter, down from their prior forecast of ($1.74). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.59) EPS, Q4 2025 earnings at ($1.44) EPS, FY2025 earnings at ($6.39) EPS and FY2026 earnings at ($6.22) EPS.

A number of other research firms have also recently issued reports on CRSP. HC Wainwright reiterated a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Bank of America reduced their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday. Barclays reduced their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Piper Sandler restated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has an average rating of "Hold" and an average price target of $71.31.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $1.45 during mid-day trading on Monday, hitting $66.70. 965,079 shares of the company's stock traded hands, compared to its average volume of 2,543,912. The firm has a 50 day simple moving average of $46.45 and a two-hundred day simple moving average of $42.40. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $71.13. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -14.90 and a beta of 1.82.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same quarter in the prior year, the firm earned ($1.43) earnings per share. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter worth approximately $3,231,000. PNC Financial Services Group Inc. boosted its position in shares of CRISPR Therapeutics by 16.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,346 shares of the company's stock worth $171,000 after buying an additional 606 shares during the period. Avantax Advisory Services Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth $269,000. Swiss National Bank boosted its position in shares of CRISPR Therapeutics by 1.0% during the fourth quarter. Swiss National Bank now owns 159,100 shares of the company's stock worth $6,262,000 after buying an additional 1,500 shares during the period. Finally, Commonwealth Equity Services LLC boosted its position in shares of CRISPR Therapeutics by 3.3% during the fourth quarter. Commonwealth Equity Services LLC now owns 68,614 shares of the company's stock worth $2,701,000 after buying an additional 2,206 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, Director Simeon George purchased 989,812 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were acquired at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the purchase, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider directly owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.